Longevity Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 0.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Longevity Market Analysis
The Longevity Market is expected to register a CAGR of 0% during the forecast period.
Driven by an aging global population, heightened awareness of longevity treatments, and rapid technological advancements, the longevity market is witnessing robust growth. Chronic diseases like cancer, diabetes, and cardiovascular issues, prevalent among the elderly, diminish patients' quality of life. This reality amplifies the demand for innovative technologies, further fueling market expansion. As the global geriatric population swells, so does the pool of potential patients seeking longevity treatments. Data from the United Nations, released in October 2022, underscores this trend: the global population aged 60 and above is set to surge from 1 billion in 2022 to 1.4 billion by 2030, with projections reaching 2.1 billion by 2050. Such a demographic shift promises a burgeoning demand for longevity treatments, positioning the market for significant growth opportunities.
Moreover, the rising prevalence of diabetes is driving the adoption of longevity treatments, further propelling market expansion. A January 2024 report from the National Institute of Diabetes and Digestive and Kidney Diseases highlighted that in 2022, 38.4 million Americans (11.6% of the population) had diabetes. Notably, 38.1 million of these were adults aged 18 and older, with over 29.7 million officially diagnosed.
Furthermore, a heightened emphasis on technological innovations and increased funding for novel treatment methodologies are catalyzing the growth of the longevity market. A February 2024 report from Yale University emphasized the role of groundbreaking technologies like CRISPR in this expansion. Yale's Longevity Investors Conference, a platform where affluent investors channel significant funds into anti-aging and longevity projects, underscores the global pivot towards valuing an extended healthspan and lifespan through cutting-edge research. Highlighting this trend, age1, a venture capital firm with a focus on longevity biotech, secured an initial fund of USD 35 million in September 2023, aiming to transition the focus from mere 'sick care' to proactive health preservation and lifespan extension.
Technological strides, especially in regenerative medicine and artificial intelligence, are not only addressing age-related ailments but are also enhancing overall health outcomes. An October 2023 report from Tomorrow Bio noted that AI's integration into healthcare is revolutionizing patient care, with predictive systems identifying potential diseases early, thereby positively influencing life expectancy.
Given these dynamics, the longevity market is poised for growth, driven by an aging population and intensified research into novel technologies. Yet, challenges remain. Stringent regulatory processes and ethical dilemmas surrounding longevity treatments pose significant hurdles to the market's expansion.
Longevity Market Trends
The Cancer Segment is Expected to Hold a Major Market Share Over the Forecast Period
The longevity market is reshaping healthcare by emphasizing interventions that not only enhance the quality of life and promote healthy aging but also have the potential to extend lifespan. Cancer, a leading age-related disease, is at the forefront of this market's focus. Through innovative interventions like cellular senescence, DNA damage repair, and immunosenescence, the longevity market is introducing groundbreaking cancer treatment methods, driving its expansion. Additionally, the surge in cancer cases in recent years further fuels this market growth.
Cancer poses a significant global health challenge and ranks as a primary cause of mortality. For example, a report from the Lung Cancer Foundation in January 2024 highlighted a concerning trend in India. The study projected a 12.8% rise in annual cancer cases, estimating an increase from 1.46 million in 2022 to approximately 1.57 million by 2025.
Technological advancements in the cancer domain are further energizing the longevity market. A December 2022 report from the Journal of Gerontology emphasized that breakthroughs in understanding aging processes, like cellular senescence, illuminate the link between aging and cancer. This insight drives research towards interventions targeting these aging mechanisms.
Such innovations not only promise to revolutionize cancer care by curbing its development and progression but also bolster the expanding longevity market. Notable examples, such as geroscience-guided interventions and senolytics, underscore the potential of longevity-centric technologies in cancer prevention and survivorship.
Given the escalating cancer prevalence and the rise of advanced technological treatments, the market is poised for significant growth in the coming years.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America's sophisticated healthcare infrastructure boasts an extensive network of advanced hospitals and cancer care facilities, all equipped with cutting-edge technology. This setup facilitates the widespread adoption of longevity treatments.
The rising cancer burden in the U.S. is a primary driver for the demand for longevity treatments in cancer management. For instance, a report from the Cancer Journal for Clinicians in January 2024 projected two million new cancer cases in the U.S. for the year. Furthermore, the American Cancer Society's "Cancer Facts and Figures 2023" estimated 1.95 million new cancer cases in 2023, with 1.01 million males and 0.94 million females affected.
These statistics underscore the escalating cancer burden, suggesting a growing demand for effective longevity treatments. Consequently, this rising cancer prevalence is poised to fuel the country's market growth.
Moreover, the uptick in age-related diseases presents lucrative opportunities for the longevity market in the region. Take Canada, for instance: with its aging population, there's a noticeable rise in joint pain and osteoarthritis cases. According to 2023 data from the United Nations Population Fund, 20% of Canada's population was aged 65 and above. This significant aging demographic is likely to amplify the osteoarthritis burden, further propelling the longevity market.
In summary, the surging prevalence of age-related disorders, notably cancer and osteoarthritis, in North America is catalyzing robust growth in the longevity market.
Longevity Industry Overview
The longevity market is moderately fragmented and consists of several major players. Some companies currently dominating the longevity market are Bristol-Myers Squibb, Merck Co. Inc., Pfizer Inc., AbbVie, and Eli Lilly and Company.
Longevity Market Leaders
-
Bristol-Myers Squibb
-
Merck Co. Inc.
-
Pfizer Inc.
-
AbbVie
-
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Longevity Market News
- April 2024: The Indian Institute of Science (IISc) has unveiled its 'Longevity India' initiative. Aimed at deepening the comprehension of aging, this initiative emphasizes both fundamental and applied research, striving to craft solutions that elevate the quality of life.
- August 2023: Serina Therapeutics has signed a merger agreement with a subsidiary fully owned by AgeX Therapeutics, a company specializing in longevity.
Longevity Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Aging Population
4.2.2 Increasing Prevalance of Chronic Diseases
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Stringent Regulatory Approval
4.3.2 Ethical Dilemma Surrounding Longevity
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Therapy
5.1.1 Senolytic Drug Therapy
5.1.2 Gene Therapy
5.1.3 Immunotherapy
5.1.4 Others
5.2 By Application
5.2.1 Cancer
5.2.2 Diabetes
5.2.3 Cardiovascular Diseases
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb
6.1.2 Merck Co. Inc.
6.1.3 Pfizer Inc.
6.1.4 AbbVie
6.1.5 Eli Lilly and Company
6.1.6 Serina Therapeutics
6.1.7 GlaxoSmithKline PLC
6.1.8 Unity Biotechnology
6.1.9 Calico Lifesciences LLC
6.1.10 CohBar Inc.
6.1.11 Life Biosciences Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Longevity Industry Segmentation
As per the scope of the report, longevity is about living with a higher quality of life and foreseeing and preventing common chronic diseases that often accompany the aging process. The longevity market is segmented by therapy, application, and geography. The market is segmented by therapy into senolytic drug therapy, gene therapy, immunotherapy, and others. The application segment is further divided into Cancer, Diabetes, Cardiovascular Diseases, and Others. The geography region is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the market sizes and forecasts for major countries across different regions. The market size is provided for each segment in terms of value (USD).
| By Therapy | |
| Senolytic Drug Therapy | |
| Gene Therapy | |
| Immunotherapy | |
| Others |
| By Application | |
| Cancer | |
| Diabetes | |
| Cardiovascular Diseases | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Longevity Market Research Faqs
What is the current Longevity Market size?
The Longevity Market is projected to register a CAGR of 0% during the forecast period (2024-2029)
Who are the key players in Longevity Market?
Bristol-Myers Squibb, Merck Co. Inc., Pfizer Inc., AbbVie and Eli Lilly and Company are the major companies operating in the Longevity Market.
Which is the fastest growing region in Longevity Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Longevity Market?
In 2024, the North America accounts for the largest market share in Longevity Market.
What years does this Longevity Market cover?
The report covers the Longevity Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Longevity Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Longevity Industry Report
Statistics for the 2024 Longevity market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Longevity analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
